Health industries

  • Webcast
    Pharmaceutical & Life Sciences Tax Hot Topics webcast: Legislative Update and Year End Accounting Update - December 10, 2014

    11/20/14 | Pharmaceuticals & life science

    Please join PwC for a complimentary Pharmaceutical and Life Sciences Tax Technical Hot Topics webcast: Legislative Update and Year End Accounting Update on Wednesday, December 10, 2014 from 12:00pm - 1:00pm (US ET).

  • Webcast
    Healthcare, Higher Education, and Nonprofit: Year end review and 2015 outlook with perspectives from the IRS webcast - December 17, 2014

    11/20/14 | Healthcare

    Please join PwC for a "Year End Review and 2015 Outlook with Perspectives from the IRS" as our tax specialists and IRS officials, Sunita Lough, Commissioner of Tax-Exempt and Government Entities, and Eric San Juan, Senior Technical Advisor to the Commissioner TE/GE, review the past year, discuss the IRS restructuring of the TE/GE Division, provide an outlook of potential future initiatives from the IRS, and highlight other issues impacting universities, healthcare providers, and other tax-exempt organizations.

  • Research and Development (R&D) Funding Arrangements

    11/18/14 | Pharmaceuticals & life science

    This Pharmaceutical and Life Sciences Alert focuses on Research and Development (R&D) Funding Arrangements.

  • Pharmaceutical and Life Sciences: 2014 SEC comment letter trends

    11/14/14 | Health Research Institute

    Our 2014 SEC comment letter trend compiles and analyzes the SEC staff’s comment letters issued over the past few years to registrants across different sectors within the Pharmaceutical and Life Sciences industry and provides highlights surrounding current hot topics and sample comments.

  • HR Innovation – Fall 2014

    10/29/14 | Human resource services

    HR Innovation offers advanced thinking about the challenges that should be uppermost on the minds and agendas of organizations and their Human Resources (HR) leaders.

  • Consumer Intelligence Series - The Wearable Future

    10/21/14 | Entertainment & media

    The Wearable Future, which looks at some of the strengths and opportunities for wearable tech—and the weaknesses and challenges that enterprising businesses must successfully navigate.

  • Change in timing for recording the Annual Pharmaceutical Fee

    10/15/14 | Pharmaceuticals & life science

    This Pharmaceutical and Life Sciences Alert focuses on the change in timing for the Annual Pharmaceutical Fee.

  • Webcast
    Healthcare Higher Education and Not-For-Profit Series - Hot Topics and Technical Updates Impacting Accounting and Financial Reporting - October 23, 2014

    10/14/14 | Healthcare

    This webcast will cover FASB standard setting developments that have occurred since our July webcast. Among other matters, we will cover developments related to the FASB/IASB convergence projects, including information related to the new revenue recognition standard, and an update on FASB projects impacting not-for-profit entities, including the not-for-profit financial statement project. As always, the focus is on not-for-profit organizations that apply FASB standards, with an emphasis on healthcare and higher education institutions.

  • Rx Marketplace Quarterly, Issue3

    10/2/14 | Pharmaceuticals & life science

    The PwC Rx Marketplace Quarterly features a wide range of financial reporting developments, accounting and tax developments, regulatory updates and general industry trends impacting the pharmaceutical and life sciences industry.

  • The rise of retail health insurance exchanges

    9/16/14 | Healthcare

    As health insurance becomes more consumer centric, employers must decide about exchanges: public, private, or none of the above. Early tremors in the market suggest a coming paradigm shift from a business-to-business model toward a business-to-consumer model of purchasing healthcare.

  • Webcast
    Pharmaceutical & Life Sciences Tax Hot Topics webcast: Medical Device Excise Tax - September 23, 2014

    9/15/14 | Pharmaceuticals & life science

    Please join PwC for a complimentary Pharmaceutical and Life Sciences Tax Technical Hot Topics webcast: Federal Medical Device Excise Tax (MDET); including a Legislative Update, IRS Audit Program and Planning Opportunities on Tuesday, September 23, 2014 from 12:00pm - 1:00pm (US ET).

  • MoneyTree™ Life Sciences Report

    9/10/14 | Healthcare

    Biotech soars to record high: Investment in biotechnology was the highest since the start of the MoneyTree data series in 1995. Biotech and medical devices industries both see year-over-year double-digit growth in investments.

  • Q2 2014 US Health Services deals insights

    8/27/14 | Transaction services

    We see a steady pace in the volume of deals for the health services sectors from the first to second quarters with 143 and 138 announced deals (281 total deals), respectively. This volume is also consistent on a year to date basis with 2013 and its 289 announced deals. However, we also note that on a quarterly basis, the second quarter of 2014’s deal volume (138 deals) has declined almost 13% from the same period in 2013 (158 deals).

  • Webcast
    Employee Benefit Plans - 2014 Plan Sponsor Update - September 10, 2014


    Michele Weldon, PwC's National Employee Benefit Plan Practice Leader, will provide an overview of current developments related to Defined Benefit, Defined Contribution, and Health & Welfare employee benefit plans. This will include an update on recent changes in accounting, auditing and regulatory requirements impacting employee benefit plans.

  • An HR perspective: Nothing but change for healthcare industry stakeholders

    8/5/14 | Human resource services

    Health care organizations today find themselves amid transformation on numerous fronts: everything from merging provider organizations to converging providers and payors to changing compensation models. Many of these changes are starting to reflect an Affordable Care Act America, along with more general shifts in the US healthcare industry—all of which yield implications for stakeholders across the board, including executives, employees, and physicians.

  • PwC's 2014 Health and Well-being Touchstone Survey results

    6/27/14 | Human resource services

    PwC is pleased to announce the availability of our 2014 Health and Well-being Touchstone Survey results. The 2014 survey data contains detailed benefits information provided by approximately 1,200 participating companies in 35 different industries across the nation.

  • Medical Cost Trend: Behind the numbers 2015

    6/26/14 | Health Research Institute

    The story of 2015 is a nuanced one. At first glance, the health sector appears to be reverting to historical patterns of bouncing back as the nation recovers from the economic doldrums. Whether spending more freely because of the improved economy or shopping with insurance provided through the Affordable Care Act, consumers triggered the first bump in growth in the first quarter of 2014. We expect that to continue through next year.

  • In depth: Revenue standard is final – A comprehensive look at the new model (Pharmaceutical & Life Sciences industry supplement)

    6/19/14 | Assurance services

    The FASB and IASB have issued their long-awaited converged standard on revenue recognition. How will you be affected? This industry-specific supplement to our In depth publication highlights some of the areas that could create the most significant challenges for Pharmaceutical & Life Sciences companies as they transition to the new revenue standard.

  • Webcast
    Revenue Recognition Webcast & Industry Supplement - Pharmaceutical and Life Sciences Companies - June 25, 2014

    6/11/14 | Pharmaceuticals & life science

    Join us for an expanded discussion on the specific impacts the new revenue recognition standard will have on the Pharmaceutical and Life Sciences industry and download our P&LS Industry Supplement.

  • Q1 2014 US Health Services deals insights

    5/21/14 | Transaction services

    In the first quarter of 2014, the total volume of deals remained consistent with the same period in 2013; however, the value of announced deals rose 152% to $12.3 billion.

  • IPR&D acquired in a business combination – How many pieces?

    5/21/14 | Pharmaceuticals & life science

    This Pharmaceutical and Life Sciences Alert focuses on in-process research and development (IPR&D) in acquisition accounting.

  • Market trends in retiree healthcare and financial reporting implications

    4/30/14 | Human resource services

    This Insight focuses on the accounting implications of changes in the design of retiree health benefit plans.

  • Final rules describe ACA health coverage reporting requirements for 2015

    4/23/14 | Human resource services

    Final regulations on ACA reporting requirements give needed guidance to employers and insurers who must report to the IRS about 2015 health coverage.

  • Potential impacts to Pharma and Life Sciences companies of the new accounting definition of an "investment company"

    4/10/14 | Pharmaceuticals & life science

    This Pharmaceutical and Life Sciences Alert focuses on the key accounting considerations when assessing whether an entity is an investment company under the new accounting definition and provides illustrative examples.

  • Rx Marketplace Quarterly Newsletter

    3/27/14 | Pharmaceuticals & life science

    The PwC Rx Marketplace Quarterly features a wide range of financial reporting developments, accounting and tax developments, regulatory updates and general industry trends impacting the pharmaceutical and life sciences industry. Each quarterly also shares strategies that companies can use to unlock divestiture value, as well as links to publications and online resources. In the spotlight in this issue is our summary of the IPO market, which has seen its most robust year since 2007. We cover key metrics for the past year, assess the industry’s top registrants, and offer a snapshot of IPO activity during the first two months of 2014.

  • Pharmaceutical Commerce: Top health industry issues for life sciences in 2014

    3/25/14 | Pharmaceuticals & life science

    Pharmaceutical Commerce: Top health industry issues for life sciences in 2014

  • US health services deals insights: analysis and trends in US health services activity 2013 and 2014 outlook

    3/24/14 | Transaction services

    In 2013, the most notable deal activity was in the hospital sector. While hospital deal volume was down, hospital deal value increased from $1.9 billion in 2012 to $18.6 billion in 2013.

  • An HR perspective, The Future of Healthcare Benefits - Employers’ opportunity for strategic change in the new healthcare world

    3/13/14 | Human resource services

    PwC recently convened several roundtables of employers in New York, Chicago, and Atlanta to discuss health coverage at this pivotal moment. This thought leadership article highlights the conversations and results of the related survey.

  • Economic Impact of Trade Secret Theft

    2/25/14 | Forensic services

    News stories, international negotiations, and recent case law continue to demonstrate the importance of securing trade secrets as a means of ensuring prosperity for companies operating in the U.S. and abroad.

  • Overcoming challenges of leading innovation in medical technology and research in the global market

    2/25/14 | Forensic services

    Promoting healthcare solutions worldwide requires navigation of the complex and constantly changing landscape of US export control laws. How regulatory controls apply to medical devices, pharmaceuticals, and biotechnology products is unique, and understanding where and how to export these products is critical to competing in the global market. This piece discusses the effect of “dual use” controls, defense regulations, and OFAC sanctions on these products, and the risks and opportunities for this booming industry.

  • Distinguishing a Business from an Asset or a Group of Assets

    1/16/14 | Pharmaceuticals & life science

    This Pharmaceutical and Life Sciences Industry GAAP Alert focuses on the key accounting considerations when making this determination and provides illustrative examples.

  • Healthcare provider: 2013 SEC comment letter trends

    1/6/14 | Health Research Institute

    To help registrants gain insight into the SEC’s current areas of interest, PwC analyzed comments released by the SEC staff to domestic large accelerated, accelerated and non-accelerated registrants within the healthcare provider industry during the three year period ended September 30, 2013.

  • Top health industry issues of 2014

    12/11/13 | Health Research Institute

    The 2014 Top Issues report examines the shifting healthcare landscape and offers insights on how to survive rising expectations and tough competition.

  • Video
    Healthcare costs and the Affordable Care Act

    12/10/13 | Assurance services

    PwC's Jay Seliber, Michael Thompson and Ken Stoler discuss the Affordable Care Act and accounting implications for retiree medical plans.

  • US GAAP: Issues and solutions for pharmaceuticals and life sciences industry

    11/20/13 | Pharmaceuticals & life science

    This publication highlights factors the industry should consider and provides guidance on the most pertinent accounting solutions under US GAAP. The solutions presented are meant to provide a framework for determining the appropriate accounting answer for general solutions.

  • Contingent Consideration in a Business Combination

    10/16/13 | Pharmaceuticals & life science

    This Pharmaceutical and Life Sciences Industry Alert provides guidance on the accounting for contingent consideration arrangements in business combinations.

  • 10Minutes
    10Minutes on drug value in the New Health Ecosystem

    7/31/13 | Pharmaceuticals & life science

    Pharmaceutical companies stand ready to be tested in a world where a drug’s success is more closely tied to its performance. The challenges mount with competition from generics and growing pressure to reduce costs. Now, insurers and integrated providers are driven by models that reward health outcomes and cost savings. For success, drug makers are exploring real-world evidence, new payment models, and the right partnerships.

  • M&A snapshot
    We’re acquiring a company with significant in-process research and development (IPR&D) activities. What's next? (M&A snapshot)

    4/23/13 | Assurance services

    This edition of Mergers & acquisitions — a snapshot provides an overview of the accounting rules and a glimpse into some of the issues companies face in the accounting and valuation of acquired IPR&D.